- Home
- WELL vs BMY Comparison
WELL vs BMY Comparison
Compare WELL & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WELL
- BMY
- Stock Information
- Founded
- WELL 1970
- BMY 1887
- Country
- WELL United States
- BMY United States
- Employees
- WELL N/A
- BMY N/A
- Industry
- WELL Real Estate Investment Trusts
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- WELL Real Estate
- BMY Health Care
- Exchange
- WELL Nasdaq
- BMY Nasdaq
- Market Cap
- WELL 112.0B
- BMY 99.7B
- IPO Year
- WELL N/A
- BMY N/A
- Fundamental
- Price
- WELL $167.67
- BMY $46.69
- Analyst Decision
- WELL Buy
- BMY Hold
- Analyst Count
- WELL 9
- BMY 15
- Target Price
- WELL $174.44
- BMY $57.64
- AVG Volume (30 Days)
- WELL 2.2M
- BMY 9.6M
- Earning Date
- WELL 10-27-2025
- BMY 10-30-2025
- Dividend Yield
- WELL 1.76%
- BMY 5.32%
- EPS Growth
- WELL 67.69
- BMY N/A
- EPS
- WELL 1.76
- BMY 2.49
- Revenue
- WELL $9,277,824,000.00
- BMY $47,704,000,000.00
- Revenue This Year
- WELL $27.79
- BMY N/A
- Revenue Next Year
- WELL $13.53
- BMY N/A
- P/E Ratio
- WELL $95.25
- BMY $18.77
- Revenue Growth
- WELL 31.96
- BMY 2.57
- 52 Week Low
- WELL $122.18
- BMY $42.96
- 52 Week High
- WELL $171.09
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- WELL 58.93
- BMY 45.96
- Support Level
- WELL $166.98
- BMY $46.65
- Resistance Level
- WELL $169.47
- BMY $48.51
- Average True Range (ATR)
- WELL 2.29
- BMY 0.91
- MACD
- WELL -0.06
- BMY -0.07
- Stochastic Oscillator
- WELL 78.08
- BMY 11.62
About WELL Welltower Inc.
Welltower owns a diversified healthcare portfolio of 2,336 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.